Physician profile
Tadele W Desalew
NPI 1528226719
$2,567.90
in general payments reported to CMS, 2019-2025
30 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $388 · 2021: $287 · 2022: $11.71 · 2023: $66.59 · 2024: $414 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $342.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $295.75 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $230.67 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.62 | 2020-2025 | Jardiance, Tradjenta |
| Medtronic, INC. | $133.56 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $127.77 | 2019-2020 | |
| Insulet Corporation | $113.44 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $106.57 | 2019-2025 | Korlym |
| Amgen INC. | $101.99 | 2024-2025 | Tepezza, Prolia, Evenity |
| Madrigal Pharmaceuticals | $88.41 | 2025 | Rezdiffra |
| Cequr Corporation | $83.08 | 2024-2025 | Cequr Simplicity |
| Abbvie INC. | $82.65 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $68.28 | 2024-2025 | Unithroid |
| Acella Pharmaceuticals, LLC | $66.59 | 2023 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $60.35 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $57.09 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $56.18 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Echosens North America, INC. | $52.61 | 2025 | Fibroscan |
| Dexcom, INC. | $46.57 | 2021-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $45.65 | 2025 | Twiist |
| Medtronic Minimed, INC. | $44.67 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $39.36 | 2024-2025 | Strensiq |
| Janssen Pharmaceuticals, INC | $33.57 | 2019-2020 | |
| Becton, Dickinson and Company | $24.02 | 2020 | |
| Glaxosmithkline, LLC. | $22.19 | 2025 | Shingrix |
| Ultragenyx Pharmaceutical INC. | $21.77 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2020 | |
| Horizon Therapeutics Plc | $15.88 | 2020 | |
| Amarin Pharma, INC. | $15.08 | 2020 | |
| Covidien LP | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tadele Desalew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.